The Series E financing will go, in part, toward expansion of the company's US presence by growing its workforce and marketing to more American hospitals.
The Guardian reports that biotech in the UK has been reaping investments despite the upcoming Brexit.
The company, which had raised $55.5 million in February, said its investors have agreed to contribute an additional $30 million.
Foresite Capital and F-Prime Capital joined previous investors in this second Series B closing, bringing the total Series B value to £33 million.
The companies will bring NIPD Genetics' Veracity and Veragene noninvasive prenatal tests to Medicover's markets, as well as developing new genetic tests.
The five startup companies are focused on molecular diagnostics, precision oncology, personalized medicine, and more.
The funding will support efforts to convert PGDx's technology, including both tissue and liquid biopsy tests, for dissemination as regulated IVD kits.
The new hardware expands Garvan's current system so that it can better support large-scale whole-genome and single-cell sequencing initiatives.
The Genome Canada program will encourage the formation of private-public partnerships to develop gene-based technologies for healthcare and agriculture.
Built by two of the creators of Nextflow, former Techstars company Lifebit makes scaleable genomic analysis technology that runs in the cloud.
An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.
An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.
Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.
In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.